The NFU program ' To do or not to do?' is making healthcare providers aware of care that adds value to patients. Recently this program received a follow-up subsidy of 3 million euros from the Citrien Fund for the period 2019-2022. With this grant, successful projects from the 2015-2018 program period can be upscaled, more healthcare providers will get involved and new projects will be started in 2019.The program started in 2015 as part of the Citrien Fund and is a collaboration of eight UMCs, dozens of hospitals, independent treatment centers, GP practices and other cooperation partners. The program received a great deal of media attention with the 1300 do-not-do-recommendations for medical specialists. Following these recommendations, nurses and general practitioners formulated their own sets. In addition, eight projects were selected where healthcare professionals, together with patients, reduced low-value care in their daily practices. You will find a comprehensive overview of the program and the results in the report ‘Doen of laten in de gezondheidszorg?’. The coming program period will focus on upscaling of the successful projects.
Call for new projects
Are you a healthcare professional with ideas on how to reduce low-value care? Until May 6 you will find a call at the Doenoflaten.nl website, open to projects from healthcare providers who want to reduce low-value care. Selected projects receive financial and de-implementation support from the 'To do or not to do?' program.
More information on the website
Related news items
How do we keep new technology affordable to improve the lives of people?16 May 2019
Improving healthcare by means of new technological developments? We need to change the entire approach for evaluating the true impact , says Maroeska Rovers. By bringing together all stakeholders from the beginning, millions of euros can be saved.read more
Algorithm calculates the presence and aggressiveness of prostate tumors14 May 2019
A computer program that analyzes MRI images can reliably map the presence and even the aggressiveness of a prostate tumor. This is what Radboudumc researchers and international colleagues have published in the scientific journal Investigative Radiology.read more
Universal tumor BRCA1/2 testing of ovarian cancer13 May 2019
Marjolijn Ligtenberg, Janet Vos and Nicoline Hoogerbrugge, assessed the feasibility of a workflow for universal tumor DNA BRCA1/2 testing of all newly diagnosed OC patients as prescreen for PARPi treatment and cancer predisposition testing. They have published their findings in the JNCI.read more
Association of gestational weight gain with adverse maternal and infant outcomes13 May 2019
An individual participant meta-analysis published in JAMA showed that pregnancy BMI is related stronger to maternal and infant complications than to gestational weight gain. The PRIDE Study, with coauthors Marleen van Gelder and Nel Roeleveld, was one of the participating cohorts.read more